Vanda Pharmaceuticals (NASDAQ: VNDA) director files initial Form 3 ownership

Rhea-AI Filing Summary

Vanda Pharmaceuticals Inc. director Duncan Charles Cliff filed an initial statement of beneficial ownership on Form 3. This filing identifies him as a director of Vanda and provides a baseline disclosure of his equity position and reporting status, without showing any reportable transactions in the provided data.

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"initial statement of beneficial ownership on Form 3 for an insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"reportingPersons list includes Duncan Charles Cliff as a director"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Duncan Charles Cliff

(Last) (First) (Middle)

2200 PENNSYLVANIA AVENUE NW

SUITE 300E

(Street)

WASHINGTON DISTRICT OF COLUMBIA 20037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/22/2026

3. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Charles Cliff Duncan	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Vanda Pharmaceuticals (VNDA) Form 3 for Duncan Charles Cliff show?

The Form 3 shows that Duncan Charles Cliff is a director of Vanda Pharmaceuticals Inc. It serves as his initial disclosure of beneficial ownership in the company and establishes a baseline for any future insider transaction reports.

Does the VNDA Form 3 for Duncan Charles Cliff report any stock transactions?

No, the Form 3 data provided shows no reported transactions. All transaction-related counts, such as buys, sells, exercises, gifts, and tax withholdings, are listed as zero, indicating this filing is purely an initial ownership statement.

Why is a Form 3 important for Vanda Pharmaceuticals (VNDA) directors?

Form 3 is important because it discloses a director’s initial beneficial ownership when they become an insider. It creates a starting point against which future Forms 4 and 5 can be compared to track changes in their holdings over time.

Who is the reporting person on the Vanda Pharmaceuticals (VNDA) Form 3?

The reporting person is Duncan Charles Cliff, identified as a director of Vanda Pharmaceuticals Inc. The filing records his insider status and fulfills SEC requirements for initial beneficial ownership reporting when someone becomes an officer, director, or large shareholder.

Does the VNDA Form 3 include any derivative securities information?

The provided Form 3 data shows an empty derivativeSummary, meaning no derivative securities such as options or warrants are listed in this excerpt. The filing here focuses on establishing the insider’s status without detailing derivative positions.